|Day's Range||2.15 - 2.34|
|52 Week Range||0.49 - 3.68|
|PE Ratio (TTM)||-3.23|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
NORCROSS, Ga., July 07, 2017-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company’ s chief operating ...
SCOTTSDALE, Ariz., June 29, 2017-- AMMO, Inc., a premier American ammunitions developer, manufacturer and distributor, today announced it has appointed two highly accomplished, senior business executives ...
Drugmakers pursuing treatments for the liver ailment NASH are struggling with a fundamental problem: How do you sell a drug for a silent disease?